FDA 510(k) Clearance: Submission Guide & Support

What does FDA 510(k) clearance establish?

A 510(k) is a premarket notification to the US FDA demonstrating that a device is substantially equivalent to an eligible legally marketed predicate. Many Class II devices, some Class I devices and certain Class III device types use this route. Many Class I types are exempt, subject to exemption limitations. Confirm the actual classification and product code before assuming a submission is needed.

Clearance is a product-specific decision, not establishment registration or a certification of every aspect of the manufacturer’s operations. Before supply, satisfy applicable registration/listing, QMSR, labeling and UDI obligations. A substantially equivalent decision should be described as “FDA cleared,” rather than “FDA approved.”

Choose the correct 510(k) approach

FDA’s 510(k) overview links the applicable routes and guidance. Decide eligibility before organizing the file or budgeting around an expected review goal.

Build a defensible predicate comparison

Start with intended use, indications, population, operator and setting. Search FDA decisions and read the predicate’s actual cleared labeling and summary. A shared product code or similar product photograph is insufficient.

Create a comparison table covering intended use, design, operating principles, materials, energy, software, patient contact, performance specifications and labeling. Explain each difference and whether it raises different questions of safety or effectiveness. Map the necessary bench, biocompatibility, electrical, sterilization, software, cybersecurity, usability and clinical evidence where applicable. Keep model numbers, software versions and tested configurations consistent throughout.

If there is no suitable predicate, assess De Novo or PMA rather than forcing a comparison. Use a focused Pre-Submission when an unresolved evidence question could lead to expensive repeat testing.

eSTAR preparation and submission

Covered 510(k)s require the FDA eSTAR template unless exempted. The form structures the content; the CDRH Portal delivers CDRH submissions. Our eSTAR guide explains the evidence map, attachment review and technical-screening preparation.

For FY 2027, October 1, 2026–September 30, 2027, FDA lists a US$28,653 standard 510(k) fee and US$7,163 qualified-small-business fee in its official schedule. Confirm eligibility and payment timing before submission. These government fees exclude testing, consulting and annual establishment registration.

FDA review and response planning

A properly prepared eSTAR is generally subject to virus scanning and technical screening rather than the conventional refuse-to-accept review. The template does not guarantee acceptance: inaccurate answers or irrelevant attachments can cause a screening hold. During substantive review, FDA can request additional evidence or clarification.

The commonly cited 90 FDA-day review goal is not a promise of clearance in 90 calendar days. Applicant response holds, evidence generation and the applicable submission type affect total elapsed time. Track every deficiency against the revised answer, supporting evidence, owner and due date. Review any new evidence for effects on the predicate comparison and labeling.

An NSE decision requires analysis of the actual deficiency; it does not automatically make a device eligible for De Novo. After clearance, assess changes before implementation and maintain complaint/reporting procedures. Pure Global can support pathway assessment, evidence planning, package preparation and FDA responses.

Our cleared, approved and granted comparison explains how to describe each authorization accurately.